Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor

Phase 2 Completed 10 enrolled Vanderbilt University Medical Center

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether exenatide can cause weight loss in patients with a history of craniopharyngioma or other brain lesion.

Timeline

Start: 2012-06
Primary completion: 2015-03
Completion: 2015-03

Outcome

Missed primary endpoint

paper Change in weight with exenatide therapy was not significant (-1.4 ± 4.3 kg [95% CI -4.9 to 2.2], P = 0.40) PMID 27133664 ↗

Publications

Results Lomenick JP, Buchowski MS, Shoemaker AH. A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity. Obesity (Silver Spring). 2016 Jun;24(6):1222-5. doi: 10.1002/oby.21493. Epub 2016 May 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Exenatide	Peptide	10 ug	—